Abstract: A buccal tablet formulation has a polyvinylpyrrolidone K-90 as a solid dispersion polymer, a hydroxypropyl methylcellulose as a mucoadhesive polymer, a sodium deoxycholate as mucopenetration enhancer, a porous silicon dioxide (e.g., FujiSil), mannitol, and avanafil. The ratio of PVP K-90 to AVA is approximately 2:1 (e.g., 2.3:1 to 1.7:1) in the tablet. Methods of making the buccal tablet with enhanced bioavailability and prolonged duration and methods of using the formulation for the treatment of erectile dysfunction are also provided.

Abstract: A buccal tablet formulation has a polyvinylpyrrolidone K-90 as a solid dispersion polymer, a hydroxypropyl methylcellulose as a mucoadhesive polymer, a sodium deoxycholate as mucopenetration enhancer, a porous silicon dioxide (e.g., FujiSil), mannitol, and avanafil. The ratio of PVP K-90 to AVA is approximately 2:1 (e.g., 2.3:1 to 1.7:1) in the tablet. Methods of making the buccal tablet with enhanced bioavailability and prolonged duration and methods of using the formulation for the treatment of erectile dysfunction are also provided.

Abstract: Methoxylated flavonoids are described for their compositions and uses in hypertension treatment as vasodilators. The flavonoids are intravenously administered in a self-nanoemulsifying drug delivery system (SNEDDS) in combination with linoleic acid which provides lowering heart rate, thus suppressing reflex tachycardia elicited by the vasodilating effect of flavonoids. The compositions are used to treat or prevent acute hypertension or any acute symptoms of emergency hypertension.

Abstract: Provided are a self-nanoemulsifying 3D printer ink composition and a method of using such composition to manufacture a 3D-printed tablet having compartmentalized active pharmaceutical ingredients. In particular, the 3D-printed tablet composition includes glimepiride and/or rosuvastatin in a curcuma oil based self-nanoemulsifying drug delivery system (SNEDDS). The disclosure also provides a method of treating a metabolic disorder or disease by administering a therapeutically effective amount of the 3D-printed tablet to a subject in need thereof.

Abstract: An ophthalmic formulation comprising transethosomes is provided. The transethosomes include a phospholipid, an edge activator, ethanol, and ketoconazole, wherein a surface of the transethosome is modified with a cationic charge inducing agent. The transethosomes may be incorporated into in situ gelling or hydrogel compositions. The formulations are useful for the sustained delivery of ketoconazole to the posterior eye segment of a subject.

Abstract: Provided are a self-nanoemulsifying 3D printer ink composition and a method of using such composition to manufacture a 3D-printed tablet having compartmentalized active pharmaceutical ingredients. In particular, the 3D-printed tablet composition includes glimepiride and/or rosuvastatin in a curcuma oil based self-nanoemulsifying drug delivery system (SNEDDS).

Abstract: Chitosan-coated, flexible lipid-based nanoparticles are provided. The nanoparticles (“chitoplexes”) comprise an interior comprising a mixture of a phospholipid, an edge activator, a charge inducing agent, and a statin; and an exterior chitosan coating which encapsulates the interior mixture. The chitoplexes exhibit enhanced bioavailability with respect to delivering the statins encapsulated therein to a subject, for example, for the treatment of cancer.

Abstract: An in situ gel formulation comprising poly lactide-co-?-caprolactone (PLCL), a surfactant with a hydrophilic-lipophilic balance value of 14-15, a plasticizer, and a statin is provided. Methods of treating hyperlipidemia by parenterally administering the in situ gel formulation are also provided.

Abstract: Micelle formulations comprising a tocopherol or derivative thereof, alpha lipoic acid, and a biologically active agent such as vinpocetine are provided. Films for transdermal delivery containing the micelle formulation and methods of treating cognitive and cerebrovascular disorders are also provided.

Abstract: Methods of enhancing cognition and/or memory and methods of treating cognitive and cerebrovascular disorders by intranasally administering an in situ gelling composition comprising micelles formed with tocopherol or a derivative thereof are provided. The micelles encapsulate a biological active agent such as vinpocetine. The methods provide for enhanced brain targeting of the biological active agent.

Abstract: Mucoadhesive buccal films comprising a statin-hydroxypropyl-beta-cyclodextrin inclusion complex and a statin-loaded mixed micelle composition, wherein the ratio of the mixed micelle composition to the inclusion complex is from 2:0.5 to 2:1.5 are provided. Methods of improving permeation of a statin across mucosal tissue by administering the film to a subject are also provided.

Abstract: Solid dosage pullulan-based buccal tablets containing a polyvinyl pyrrolidone and vinpocetine (e.g., lyophilized polyvinyl pyrrolidone vinyl acetate and vinpocetine), when administered via the buccal mucosa, provide increased bioavailability of the active agent. The formulations may be used to treat a variety of indications for which vinpocetine has been shown to have beneficial activity, and have particular utility in the treatment of cerebral degenerative diseases.